These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402 [TBL] [Abstract][Full Text] [Related]
4. Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel. Terao T; Kitamura W; Fujii N; Asada N; Kamoi C; Fujiwara K; Kondo K; Matsubara C; Hayashino K; Seike K; Fujiwara H; Ennishi D; Nishimori H; Fujii K; Matsuoka KI; Maeda Y Transplant Cell Ther; 2023 Sep; 29(9):573.e1-573.e8. PubMed ID: 37394114 [TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168 [TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519 [TBL] [Abstract][Full Text] [Related]
10. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P; Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100 [TBL] [Abstract][Full Text] [Related]
11. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738 [TBL] [Abstract][Full Text] [Related]
12. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z Front Immunol; 2022; 13():969660. PubMed ID: 36059523 [TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M Front Immunol; 2021; 12():745320. PubMed ID: 34712233 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. Fukuhara N; Kato K; Goto H; Takeshi T; Kawaguchi M; Tokushige K; Akashi K; Teshima T; Harigae H; Schuster SJ; Thieblemont C; Dreyling M; Fowler N Int J Hematol; 2023 Feb; 117(2):251-259. PubMed ID: 36404384 [TBL] [Abstract][Full Text] [Related]
18. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609 [TBL] [Abstract][Full Text] [Related]
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]